idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
08.06.2023 08:54

Alcohol drinking cut in half with diabetes medication

Press Contact: Margareta G. Kubista at the University of Gothenburg, phone +46 705 30 19 80, press@sahlgrenska.gu.se Kommunikationsavdelningen / Communications Department
Schwedischer Forschungsrat - The Swedish Research Council

    The medication semaglutide, which is currently used in the treatment of type 2 diabetes and obesity, might also be an effective medication for alcohol dependence. In a study from the University of Gothenburg, the drug reduced alcohol relapse drinking and alcohol intake in rats by more than half.

    Semaglutide is sold under brand names such as Ozempic. Since this medication was also approved for the treatment of obesity, demand has increased, which has resulted in difficulties in procuring the drug in recent times. There is anecdotal evidence of patients with obesity or diabetes saying that their craving for alcohol has lessened since they started taking the drug.

    Today, individuals with alcohol dependence are treated with a combination of various psychosocial methods and medications. Four approved medications are available. Since alcohol dependence is a disease with many causes, the efficacy of these medications varies, and so it is important that we develop additional treatment medications.

    Reduced relapses

    Semaglutide is a long-acting substance that only needs to be taken once a week. This is the first medication to act on the GLP-1 receptor that can be taken in tablet form.

    The results of the study are published in the scientific journal eBioMedicine. In the study, alcohol-dependent rats were treated with semaglutide, which significantly reduced their alcohol consumption and even reduced the drinking of alcohol in conjunction with relapses. Relapses comprise a major problem for individuals with alcohol dependence, as an individual who has abstained from alcohol for a period relapses and drink more than before the withdrawal.

    In the study, the treated rats cut their alcohol intake in half compared to animals that did not receive treatment. One interesting finding in the study was that semaglutide reduced alcohol intake equally in both male and female rats.

    Animals and humans

    The study reports a strikingly good effect, although clinical studies will be required before the medication can be used for alcohol dependence, and such studies take time. Moving forward, the medication may be of most benefit to patients suffering from both overweight and alcohol dependence. According to the researchers it is likely that these results will carry over to humans, as results from other studies on alcohol dependency medications made with the same research model have shown similar effect in humans as in rats.

    “There are, of course, differences in conducting studies on animals and humans, and these must always be taken into account. However, in this case, there is a previous study on humans in which an older version of the diabetes medications that act on GLP-1 was found to reduce alcohol intake in overweight individuals with alcohol dependence,” says Elisabet Jerlhag, professor of pharmacology at Sahlgrenska Academy at the University of Gothenburg.

    Mechanisms in the brain

    The current study also examined why the medication reduces alcohol drinking. The results indicate that reduced alcohol-induced reward could be a contributing factor. In the study, semaglutide affected the brain’s reward system in mice, to be more exact the nucleus accumbens area of the brain, which is part of the limbic system.

    “Alcohol activates the brain’s reward system, resulting in the release of dopamine, something that is seen in both humans and animals. This process is blocked by the medication in mice, and with our interpretation, this could cause a reduction in the alcohol-induced reward,” says Cajsa Aranäs, doctoral student at Sahlgrenska Academy at the University of Gothenburg, who is responsible for much of the work behind the study presented here.

    Images: Elisabet Jerlhag Holm (photo: Johan Wingborg) and Cajsa Aranäs (photo: Elin Lindström)


    Wissenschaftliche Ansprechpartner:

    Elisabet Jerlhag Holm, professor at Sahlgrenska Academy at the University of Gothenburg, phone +46 736 483 336, email elisabet.jerlhag@pharm.gu.se

    Cajsa Aranäs, doctoral student at Sahlgrenska Academy at the University of Gothenburg, phone +46 709 993 837, email cajsa.aranas@gu.se


    Originalpublikation:

    Titel: Semaglutide Reduces Alcohol Intake and Relapse-like Drinking in Male and Female Rats, The Lancet


    Weitere Informationen:

    https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00207-4/fullte...
    https://www.expertsvar.se/wp-content/uploads/2023/06/JerlhagHolm-and-Aranas.jpg


    Bilder

    Merkmale dieser Pressemitteilung:
    Journalisten
    Ernährung / Gesundheit / Pflege, Medizin
    überregional
    Forschungsergebnisse
    Englisch


     

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).